https://www.selleckchem.com/products/hs148.html
Oral eslicarbazepine acetate was generally well tolerated when administered as adjunctive therapy or monotherapy in adult patients and when administered as adjunctive therapy in paediatric patients, with most adverse events being of mild or moderate intensity. In conclusion, with the convenience of once-daily administration, eslicarbazepine acetate is an effective and generally well-tolerated treatment option for adults, adolescents and children aged 6 years with focal-onset seizures.To compare the clinical, imaging, and prognostic c
Like
Comment
Share
